A review of relevant research results shows that: the MG1-Maraba oncolytic virus (99) (carrying the STEAP vaccine) can effectively break tumor immune tolerance and realize the remodeling of the “cold” TME; reovirus (100) can target prostate cancer cells with activated Ras signaling and induce antigen-specific anti-tumor immune responses; when radiotherapy (101) is used in combination with VSV-IFNb (vesicular stomatitis virus-interferon β fusion virus), it can effectively overcome the viral resistance of tumor cells and induce long-term anti-tumor immune memory mediated by CD8+ T cells. Here, CD8A is linked to neoplasm.